Cockroach Nasal Allergen Challenge Pilot

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 11, 2017

Study Completion Date

April 11, 2017

Conditions
AsthmaCockroach Hypersensitivity
Interventions
BIOLOGICAL

Glycerinated German Cockroach Allergenic Extract

"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."

Trial Locations (4)

20010

Children's National Medical Center, Washington D.C.

45229

Cincinnati Children's Hospital, Cincinnati

75390

UT Southwestern Medical Center, Dallas

80045

Children's Hospital Colorado, Aurora

All Listed Sponsors
collaborator

Inner-City Asthma Consortium

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02710136 - Cockroach Nasal Allergen Challenge Pilot | Biotech Hunter | Biotech Hunter